Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Growth Hormone and IGF Research is Scopus-indexed (Q3, CiteScore 3.7), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Churchill Livingstone.
Checked against the index lists dated .
ISSN 1096-6374Verify ISSN ↗1532-2238Verify ISSN ↗
Publisher: Churchill Livingstone
Cost to publish: About US$3,570 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Endocrinology, Diabetes and Metabolism | 146 / 250 | 41st | Q3 |
| Endocrinology | 90 / 132 | 32nd | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1998–present, best quartile Q3, CiteScore 3.7.
Growth Hormone and IGF Research is Q3 in Endocrinology, Diabetes and Metabolism (rank 146 of 250) and Q3 in Endocrinology (rank 90 of 132), by CiteScore 2025.
Growth Hormone and IGF Research is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.7, which places it in quartile Q3 at the 41st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.633, quartile Q3, with an H-index of 72.
The publisher lists an article processing charge of about US$3,570 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Growth Hormone and IGF Research is published by Churchill Livingstone. Its print ISSN is 1096-6374 and its online ISSN is 1532-2238.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Growth Hormone and IGF Research has an h-index of 79 and a 2-year mean of 1.09 citations per paper (OpenAlex). Its Scopus CiteScore is 3.7, quartile Q3. On 2-year citations it ranks #164 of 246 Scopus journals in Endocrinology, Diabetes and Metabolism.
Growth Hormone and IGF Research published 20 papers in 2025; its busiest recent year was 2017 with 67. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2022–2026), authors are most often from United States (17.9%), Türkiye (12.1%) and Japan (9.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.